Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Roivant和Kinevant Sciences完成了评估纳米鲁单抗治疗慢性肺结节病的Resolve-Lung 2期研究的入组
Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Roivant和Kinevant Sciences完成了评估纳米鲁单抗治疗慢性肺结节病的Resolve-Lung 2期研究的入组
使用浏览器的分享功能,分享给你的好友吧